Notable co‐inhibitory receptors in this context include the T‐cell immunoreceptor with Ig and ITIM domains (TIGIT), lymphocyte activation gene 3 protein (LAG‐3), and CTLA‐4, which represent promising avenues for immunotherapy in NSCLC (Figure 1B). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.